Company Overview and News
KUALA LUMPUR: E-government service providers could be seeing more jobs in the pipeline as the government intends to pursue digitalisation agenda “aggressively” for higher digital adoption in the public service.
5216 6491 4456
KUALA LUMPUR: Dagang NeXchange Bhd 's (DNeX) indirect 51%-owned subsidiary, DNeX Telco Services Sdn Bhd, has secured two marine fibre optic cable repair contracts worth US$2.8mil from PT Bina Nusantara Perkasa.
KUALA LUMPUR (Oct 17): Based on corporate announcements and news flow today, stocks in focus on Thursday (Oct 18) may include Dagang Nexchange Bhd, Kumpulan Perangsang Selangor Bhd, Malaysian Resources Corp Bhd (MRCB), George Kent (M) Bhd, Gas Malaysia Bhd, Top Glove Corp Bhd, WCT Holdings Bhd and Press Metal Aluminium Holdings Bhd.
TGLVY 5843 3204 4456 5209 8869 7113 TPGVF 9679
WHILE crude oil has rebounded to over US$80 per barrel and sentiment on the oil and gas sector has turned bullish, the recovery in prices may not lift all players in the industry.
4456 7251 5183 PECGF 5141 HIPEF 5256 5199
KUALA LUMPUR (Oct 4): The FBM KLCI retreated at mid-morning today on sustained weaker sentiment at the domestic market.
7083 5183 5172 PECGF BATS 4162 5014 5199 4634 KLKBY 2445 5226 4456 5347 3026 0026 TNABY MYPRY 2836 TNABF HIPEF
KUALA LUMPUR (Oct 2): The FBM KLCI was hard pressed to find a firm footing in the morning session and remained below the crucial 1,800-point level at the midday break, as regional markets retreated.
HLFBF BRDBF UPBMF 1082 5168 2089 5256 5255 9334 5199 5210 4634 5139 4456 3026 0900 0026 7108 2836 HIPEF GEBHF HRGHY
KUALA LUMPUR: Oil and gas (O&G) counters on Bursa Malaysia mostly attracted renewed interest yesterday after crude oil prices breached the US$80 (RM331) a barrel level overnight.
4456 BRDBF BSMAF HIPEF 5256 5210 1818 5199
2018-09-25 theedgemarkets - 1
KUALA LUMPUR (Sep 25): Oil & gas counters rallied this morning as Brent crude oil breached the US$80 per barrel level to a four year high of US$81.30 per barrel after Saudi Arabia and Russia ruled out any immediate increase in production despite calls by US President Donald Trump for action to raise global supply.
4456 BRDBF HIPEF 5256 5210 5199
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...